##  [FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)](/us-en/news/media-releases/fda-accepts-file-and-accelerates-review-novartis-sickle-cell-disease-medicine-crizanlizumab-seg101-0 "FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)") 

  Jul 16, 2019